Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT

Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT

Practical Solutions and Value Highlights

Atopic eczema is a common childhood skin problem connected with asthma and allergies, affecting quality of life.

The study aimed to determine if advising parents to apply daily emollients in the first year can prevent eczema and other allergic conditions in high-risk children.

A pragmatic clinical trial was conducted in the UK involving healthy infants at high risk of developing eczema. Infants were randomized to apply emollient daily or receive standard skincare advice only.

The primary outcome found no evidence that daily emollient use prevents eczema in high-risk children. In fact, emollient use was associated with a higher risk of skin infections and a possible increase in food allergy.

Further investigation is required through a meta-analysis of similar studies to better understand prevention strategies.

The trial was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme.

Value in Clinical Trials

Clinical trials help develop safe and effective treatments, and it’s crucial to apply their benefits to everyday medical practice.

DocSym, an AI-driven platform, consolidates clinical knowledge and research, providing a single accessible resource for clinicians based on ICD-11 standards and clinical protocols.

Streamlining Healthcare Operations

In the current healthcare environment, it’s essential to streamline operations. Mobile apps can support scheduling, monitoring treatments, and telemedicine to improve patient care and expand digital services.

AI technology can enhance clinic workflows and improve patient outcomes while reducing paperwork.

Find out more about how AI can support healthcare at aidevmd.com.